Evidence map›Paper›PMID 37695655›Full record

ArticleJMIR cardio2023

Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study.

Kristina Klier, Yash J Patel, Timo Schinköthe, Nadia Harbeck, Annette Schmidt

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JMIR cardio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04055493 (Adjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Endocrine Therapy Plus Ribociclib Versus Chemotherapy in Intermediate Risk, HR+/HER2- Early Breast Cancer), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04055493 phase3active not recruitingnot on this map

Adjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Endocrine Therapy Plus Ribociclib Versus Chemotherapy in Intermediate Risk, HR+/HER2- Early Breast Cancer

TypeinterventionalSponsorWomen's Cancer Study Group GmbHRan2019 to 2027Enrolled1,684ConditionsBreast Cancer FemaleArmsRibociclib 200Mg Oral Tablet
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kristina KlierInstitute of Sport Science, University of the Bundeswehr Munich, Neubiberg, Germany.ORCID https://orcid.org/0000-0002-6906-9933
Yash J PatelCANKADO GmbH, Ottobrunn, Germany.ORCID https://orcid.org/0009-0007-3060-6950
Timo SchinkötheCANKADO GmbH, Ottobrunn, Germany.ORCID https://orcid.org/0000-0002-2008-6775
Nadia HarbeckDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center of the Ludwig-Maximilians-University, Munich, Germany.ORCID https://orcid.org/0000-0002-9744-7372
Annette SchmidtInstitute of Sport Science, University of the Bundeswehr Munich, Neubiberg, Germany.ORCID https://orcid.org/0000-0002-2315-6417

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNumerous antineoplastic drugs such as chemotherapeutics have cardiotoxic side effects and can lead to long QT syndrome (LQTS). When diagnosed and treated in time, the potentially fatal outcomes of LQTS can be prevented. Therefore, regular electrocardiogram (ECG) assessments are critical to ensure patient safety. However, these assessments are associated with patient discomfort and require timely support of the attending oncologist by a cardiologist.

objectiveThis study aimed to examine whether this approach can be made more efficient and comfortable by a smartphone app (QTc Tracker), supporting single-lead ECG records on site and transferring to a tele-cardiologist for an immediate diagnosis.

methodsTo evaluate the QTc Tracker, it was implemented in 54 cancer centers in Germany. In total, 266 corrected QT interval (QTc) diagnoses of 122 patients were recorded. Moreover, a questionnaire on routine ECG workflow, turnaround time, and satisfaction (1=best, 6=worst) was answered by the centers before and after the implementation of the QTc Tracker.

resultsCompared to the routine ECG workflow, the QTc Tracker enabled a substantial turnaround time reduction of 98% (mean 2.67, 95% CI 1.72-2.67 h) and even further time efficiency in combination with a cardiologic on-call service (mean 12.10, 95% CI 5.67-18.67 min). Additionally, nurses and patients reported higher satisfaction when using the QTc Tracker. In particular, patients' satisfaction sharply improved from 2.59 (95% CI 2.41-2.88) for the routine ECG workflow to 1.25 (95% CI 0.99-1.51) for the QTc Tracker workflow.

conclusionsThese results reveal a significant improvement regarding reduced turnaround time and increased user satisfaction. Best patient care might be guaranteed as the exposure of patients with an uncontrolled risk of QTc prolongations can be avoided by using the fast and easy QTc Tracker. In particular, as regular side-effect monitoring, the QTc Tracker app promises more convenience for patients and their physicians. Finally, future studies are needed to empirically test the usability and validity of such mobile ECG assessment methods.

trial registrationClinicalTrials.gov NCT04055493; https://classic.clinicaltrials.gov/ct2/show/NCT04055493.

Indexed as

adverse effectsappapplicationarrhythmiacancercardiologycardiotoxicdiagnosisdiagnosticECGeHealthelectrocardiographyheartlong QT syndromemHealthmobile healthoncologyprolonged QT intervalside effectstele-cardiologytelehealthtelemedicine

Identifiers

PMID37695655
PMCPMC10520775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.